2025
BRCA1 and BRCA2 as prognostic markers in oral squamous cell carcinoma: a minireview
GEDEONOVA, Dominika; Claretta BIANCHI; Jan STEMBIREK; Matous HRDINKA; Zuzana CHYRA et. al.Základní údaje
Originální název
BRCA1 and BRCA2 as prognostic markers in oral squamous cell carcinoma: a minireview
Autoři
GEDEONOVA, Dominika; Claretta BIANCHI; Jan STEMBIREK; Matous HRDINKA; Zuzana CHYRA; Marcela BUCHTOVÁ (203 Česká republika, domácí); Pavel HURNIK; Tomas BLAZEK a Jana REZNAROVA
Vydání
Frontiers in Oncology, Laussane, Frontiers Media SA, 2025, 2234-943X
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30204 Oncology
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.500 v roce 2023
Organizační jednotka
Přírodovědecká fakulta
UT WoS
001463362700001
EID Scopus
2-s2.0-105002227069
Klíčová slova anglicky
BRCA1; BRCA2; OSCC (oral squamous cell carcinoma); HNSCC (head and neck squamous cell carcinoma); gene alteration
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 9. 5. 2025 11:11, Mgr. Marie Novosadová Šípková, DiS.
Anotace
V originále
Oral squamous cell carcinoma (OSCC), a subset of head and neck cancers, primarily originates in the epithelial tissues of the oral cavity. Despite advancements in treatment, the mortality rate for OSCC remains around 50%, underscoring the urgent need for improved prognostic markers. This review explores the role of the BRCA1 and BRCA2 genes—traditionally associated with breast and ovarian cancers—in the context of OSCC. We discuss the molecular pathways involving BRCA genes, their potential as diagnostics and prognostic biomarkers, and their implications for personalized treatment strategies, including addressing chemotherapy resistance. Furthermore, this review emphasizes the significance of genome stability in cancer progression and examines both current and emerging methodologies for detecting BRCA mutations in OSCC patients. Despite limited prevalence of BRCA mutations in OSCC compared to other cancers, their role in DNA repair and therapeutic response underscores their potential as clinical biomarkers. However, standardized, multicenter studies are still needed to validate their utility in OSCC management. A better understanding of the role of BRCA genes in OSCC could pave the way for more effective therapeutic approaches and improved patient outcomes.